23 completed, 15 active not recruiting, 15 recruiting, 7 terminated. 41 Phase 2, 36 Phase 1, 2 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Refractory Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory Non-Hodgkin Lymphoma trials Research Report on Refractory Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma SIRPant-M, External-beam radiotherapy (XRT) - Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | SIRPant Immunotherapeutics, Inc. | 24 | 2024-01-17 | 2024-12-20 |
| First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma ARI0003 - Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 40 | 2024-01-15 | 2023-10-26 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors HCB101 - Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma | Phase 1 | Recruiting | FBD Biologics Limited | 80 | 2023-10-02 | 2026-02-04 |
| A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Completed | The First Affiliated Hospital of Soochow University | 100 | 2023-09-01 | 2026-06-03 | |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Lyell Immunopharma, Inc. | 270 | 2023-05-09 | 2026-08-25 |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy - Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Recruiting | Lazaros Lekakis | 22 | 2022-12-14 | 2025-12-31 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
Showing 20 of 68. Sign in to see all of them.
Lymphoma, Non-Hodgkin (68) · Leukemia, Lymphocytic, Chronic, B-Cell (17) · Lymphoma, Large B-Cell, Diffuse (16) · Neuroblastoma (16) · Glioma (14) · Hepatoblastoma (14) · Neuroectodermal Tumors, Primitive, Peripheral (14) · Osteosarcoma (14) · Wilms Tumor (14) · Ependymoma (13) · Histiocytosis, Langerhans-Cell (13) · Lymphoma, Follicular (13) · Rhabdoid Tumor (13) · Rhabdomyosarcoma (13) · Sarcoma (13)
Hemic and Lymphatic Diseases (68) · Immunoproliferative Disorders (68) · Lymphatic Diseases (68) · Lymphoproliferative Disorders (68) · Neoplasms by Histologic Type (68) · Immune System Diseases (67) · Neoplasms (66) · Lymphoma (63) · Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Hematologic Diseases (22) · Neoplasms by Site (21) · Disease Attributes (20) · Leukemia (19) · Leukemia, Lymphoid (19)
Cyclophosphamide (16) · Specimen Handling (10) · fludarabine phosphate (10) · Magnetic Resonance Spectroscopy (9) · fludarabine (9) · Biopsy (7) · Phantoms, Imaging (7) · Rituximab (7) · X-Rays (7) · Whole-Body Irradiation (6) · Mycophenolic Acid (5) · Nivolumab (5) · Nuclear Medicine Department, Hospital (5) · Cytarabine (4) · Melphalan (4)
National Cancer Institute (NCI) (18) · M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (3) · Marcela V. Maus, M.D.,Ph.D. (3) · The First Affiliated Hospital of Soochow University (3) · Lyell Immunopharma, Inc. (2) · Mayo Clinic (2) · Ohio State University Comprehensive Cancer Center (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · Actuate Therapeutics Inc. (1) · BeOne Medicines (1) · C. Babis Andreadis (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1)
United States (58) · Puerto Rico (14) · China (8) · Australia (6) · Canada (4) · South Korea (2) · Spain (2) · Belgium (1) · France (1) · Germany (1) · Mexico (1) · Netherlands (1) · New Zealand (1) · Portugal (1) · Taiwan (1)
Matthew Frigault, MD (2) · Sumithira Vasu, MD (2) · AeRang Kim (1) · Ajay K. Gopal (1) · Alexey Danilov (1) · Alice Lee (1) · Andrea T Franson (1) · Ariela Noy (1) · Carl E Allen (1) · Carrie Ho, MD (1) · Chelsea C Pinnix (1) · Chitra Hosing (1) · Christine A Pratilas (1) · Christopher R D'Angelo, MD (1) · Crystal L Mackall (1)
PMID 31401903, PMID 34515338, PMID 24327518, PMID 27111235, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29038338, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30728140, PMID 30729531, PMID 30782611, PMID 30975030, PMID 31101621, PMID 31219975, PMID 31335321, PMID 31533931, PMID 31648294, PMID 31831767, PMID 31882719, PMID 31894292, PMID 32192573, PMID 32499241, PMID 32967009, PMID 33591402, PMID 34113569, PMID 34486544, PMID 34666344, PMID 35353553, PMID 35363510, PMID 35432352, PMID 35815408, PMID 36131934, PMID 36631449, PMID 37774014, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39298716, PMID 39333103, PMID 39563035, PMID 39863139, PMID 39928957, PMID 40656663, PMID 41166674, PMID 41981308, PMID 42389828, PMID 42686334
U10CA180886 (14), P30CA015704 (2), P30CA016672 (2), 2025 (1), P30CA043703 (1), P30CA069533 (1), P50CA097274 (1), P50CA107399 (1), R01CA136551 (1), R01CA276374 (1), U10CA021115 (1), U10CA180820 (1), UM1CA081457 (1), UM1CA097452 (1), UM1CA121947 (1)